Patents by Inventor John Kincaid

John Kincaid has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MTORC1 MODULATORS AND USES THEREOF
    Publication number: 20240002399
    Abstract: The disclosure provides compounds and salts that show high selectivity and inhibitory activity for mTORC1 and uses thereof for the treatment of disease, such as Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 8, 2023
    Publication date: January 4, 2024
    Inventor: John Kincaid
  • MTORC1 MODULATORS AND USES THEREOF
    Publication number: 20230331737
    Abstract: The disclosure provides compounds and salts that show high selectivity and inhibitory activity for mTORC1 and uses thereof for the treatment of disease.
    Type: Application
    Filed: January 20, 2023
    Publication date: October 19, 2023
    Inventors: John KINCAID, Alexandre FROIDBISE, Guillaume EPPE
  • mTORC1 modulators and uses thereof
    Patent number: 11634432
    Abstract: The disclosure provides compounds and salts that show high selectivity and inhibitory activity for mTORC1 and uses thereof for the treatment of disease, such as Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 1, 2022
    Date of Patent: April 25, 2023
    Assignee: AEOVIAN PHARMACEUTICALS, INC.
    Inventor: John Kincaid
  • DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES
    Publication number: 20230119547
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating a condition, disease, or disorder associated with abnormal activation of the SREBP pathway, including metabolic disorders such as obesity, cancer, cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD) wherein the compound is according to Formula (I).
    Type: Application
    Filed: September 8, 2022
    Publication date: April 20, 2023
    Inventors: JOEL HUFF, Montonari Uesugi, John Kincaid
  • MTORC1 modulators and uses thereof
    Patent number: 11603377
    Abstract: The disclosure provides compounds and salts that show high selectivity and inhibitory activity for mTORC1 and uses thereof for the treatment of disease, such as Formula X: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: March 14, 2023
    Assignee: Aeovian Pharmaceuticals, Inc.
    Inventor: John Kincaid
  • Cyanoaryl-aniline compounds for treatment of dermal disorders
    Patent number: 11572344
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the compound is according to formula where R1, R2, R2a, R3, R3a, and X are as described herein.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: February 7, 2023
    Assignee: NFLECTION THERAPEUTICS, INC.
    Inventors: John Kincaid, Matthew Duncton
  • ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS
    Publication number: 20230013227
    Abstract: Provided herein are compounds and pharmaceutical compositions thereof for treating a birthmark in a subject in need thereof, wherein the compound is according to any one of formula (I), (II), (III), (IV), and (V). wherein, X1, X2, X3, R1, R2, R2a, R13, R13a, R23, R23a, R23b, R33, R33a, R33b, R43, R43a, R51, R53, R53a, R53b, bond “a”, and subscript n are described herein.
    Type: Application
    Filed: November 20, 2019
    Publication date: January 19, 2023
    Inventors: John KINCAID, Kavita Yang SARIN
  • Fused heteroaromatic-aniline compounds for treatment of dermal disorders
    Patent number: 11542271
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I): where X, R1, R2, R2a, R3, R3a, and R3b are as described herein.
    Type: Grant
    Filed: April 20, 2021
    Date of Patent: January 3, 2023
    Assignee: NFLECTION THERAPEUTICS, INC.
    Inventors: John Kincaid, Matthew Duncton
  • Di-substituted pyrazole compounds for the treatment of diseases
    Patent number: 11497738
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating a condition, disease, or disorder associated with abnormal activation of the SREBP pathway, including metabolic disorders such as obesity, cancer, cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD) wherein the compound is according to Formula (I).
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: November 15, 2022
    Assignee: FGH BIOTECH, INC.
    Inventors: Joel Huff, Motonari Uesugi, John Kincaid
  • MTORC1 MODULATORS AND USES THEREOF
    Publication number: 20220332727
    Abstract: The disclosure provides compounds and salts that show high selectivity and inhibitory activity for mTORC1 and uses thereof for the treatment of disease.
    Type: Application
    Filed: June 3, 2022
    Publication date: October 20, 2022
    Inventor: John Kincaid
  • MTORC1 MODULATORS AND USES THEREOF
    Publication number: 20220235069
    Abstract: The disclosure provides compounds and salts that show high selectivity and inhibitory activity for mTORC1 and uses thereof for the treatment of disease.
    Type: Application
    Filed: March 1, 2022
    Publication date: July 28, 2022
    Inventor: John Kincaid
  • THIENYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS
    Publication number: 20220204486
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the compound is according to formula (I): where R1, R2, R2a, R3, and R3a are as described herein.
    Type: Application
    Filed: November 20, 2019
    Publication date: June 30, 2022
    Inventors: John KINCAID, Matthew DUNCTON
  • Di-substituted pyrazole compounds for the treatment of diseases
    Patent number: 11339142
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating a condition, disease, or disorder associated with abnormal activation of the SREBP pathway, including metabolic disorders such as obesity, cancer, cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD) wherein the compound is according to Formula (I).
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: May 24, 2022
    Assignee: FGH BIOTECH, INC.
    Inventors: Motonari Uesugi, John Kincaid, Joel Huff
  • NAPHTHYRIDINONE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS
    Publication number: 20220144819
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the compound is according to formula (I): where R1, R2, R2a, R3, R3a, R3b, and subscript n are as described herein.
    Type: Application
    Filed: November 20, 2019
    Publication date: May 12, 2022
    Inventors: John KINCAID, Matthew DUNCTON
  • ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS
    Publication number: 20220087989
    Abstract: Provided herein are compounds and pharmaceutical compositions thereof for treating a skin cancer in a subject in need thereof, wherein the compound is according to any one of formula (I), (II), (III), (IV), and (V): wherein X1, X2, X3, R1, R2, R2a, R13, R13a, R23, R23a, R23b, R33, R33a, R33b, R43, R43a, R51, R53, R53a, R53b, bond “a”, and subscript n are described herein.
    Type: Application
    Filed: November 20, 2019
    Publication date: March 24, 2022
    Inventors: Kenneth Y. TSAI, John KINCAID, Kavita Yang SARIN
  • PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS
    Publication number: 20220033399
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the compound is according to Formula (I): wherein X1, R1, R2, R2a, R3, R3a, and R3b are as described herein.
    Type: Application
    Filed: August 11, 2021
    Publication date: February 3, 2022
    Inventors: John Kincaid, Matthew Duncton
  • CYANOARYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS
    Publication number: 20220009887
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the compound is according to formula where R1, R2, R2a, R3, R3a, and X are as described herein.
    Type: Application
    Filed: November 20, 2019
    Publication date: January 13, 2022
    Inventors: John KINCAID, Matthew DUNCTON
  • FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS
    Publication number: 20210380601
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I): where X, R1, R2, R2a, R3, R3a, and R3b are as described herein.
    Type: Application
    Filed: April 20, 2021
    Publication date: December 9, 2021
    Inventors: John KINCAID, Matthew DUNCTON
  • Pyrrolopyridine-aniline compounds for treatment of dermal disorders
    Patent number: 11161845
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I), where X1, R1, R2, R2a, R3, R3a, and R3b are as described herein.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: November 2, 2021
    Assignee: Nflection Therapeutics, Inc.
    Inventors: John Kincaid, Matthew Duncton
  • Fused heteroaromatic-aniline compounds for treatment of dermal disorders
    Patent number: 10988483
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I), where X, R1, R2, R2a, R3, R3a, and R3b are as described herein.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: April 27, 2021
    Assignee: NFlection Therapeutics, Inc.
    Inventors: John Kincaid, Matthew Duncton